Search Results 31-40 of 15898 for Emicizumab

  1. Belimumab in Remission of VASculitis - Mayo Clinic

    The random assignment in this study is "1 to 1" which means that participants have an equal chance of receiving belimumab or placebo. Participation eligibility.

  2. Wilms Clinical Trials - Mayo Clinic Research

    This phase III clinical trial is studying how well combination chemotherapy and surgery work in treating young patients with Bilateral Wilms tumor and children ...

  3. Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    Giving ixazomib with pomalidomide and dexamethasone may be an effective treatment for relapsed or relapsed/refractory multiple myeloma. Participation ...

  4. A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis - Mayo Clinic

    The key outcomes in the study focus on evaluation of clinical remission, defined as Birmingham Vasculitis Activity Score (BVAS)=0 with a corticosteroid dose of ...

  5. Hodgkin Clinical Trials - Mayo Clinic Research

    This phase I trial studies the side effects and the best dose of everolimus when given together with brentuximab vedotin in treating patients with Hodgkin ...

  6. Elivaldogene autotemcel (intravenous route) - Mayo Clinic

    Elivaldogene autotemcel injection is used to treat early, active cerebral adrenoleukodystrophy (CALD) in males 4 to 17 years of age. Cerebral ...

  7. Hemophilia Clinical Trials - Mayo Clinic Research

    The purpose of this study is to determine the percentage of subjects with confirmed inhibitors (per CDC laboratory criteria; >0.5 Nijmegen Bethesda Units for ...

  8. Drugs and Supplements that Start with E - Mayo Clinic

    Emicizumab-kxwh (subcutaneous route). Emla. Also known as. Lidocaine and prilocaine (topical application route). Emo-Cort. Also known as. Hydrocortisone ...

  9. A Study of Paclitaxel with or without Cixutumumab as Second-Line Therapy for Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer - Mayo Clinic

    Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more ...

  10. A Study to Evaluate if Benralizumab Compared to Mepolizumab May be Beneficial in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) - Mayo Clinic

    All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period ...